Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein

被引:0
|
作者
Xian, Jie [1 ]
Sinha, Navyaa [1 ]
Girgis, Christina [1 ]
Oh, Christopher S. [1 ]
Cring, Matthew R. [1 ]
Widhopf II, George F. [1 ]
Kipps, Thomas J. [1 ]
机构
[1] Univ Calif San Diego, Ctr Novel Therapeut, Moores Canc Ctr, Dept Med, San Diego, CA 92037 USA
关键词
ROR1; variant transcripts; neoplasia; anti-ROR1; antibody; MICRORNA DYSREGULATION; EXPRESSION;
D O I
10.3390/biomedicines12071573
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Drs. John and Ford reported in biomedicines that a variant transcript encoding receptor tyrosine kinase-like orphan receptor 1 (ROR1), namely ENST00000545203 or variant 3 (ROR1V3), was a predominant ROR1 transcript of neoplastic or normal cells in the Bioinformatic database, including GTEx and the 33 datasets from TCGA. Unlike the full-length ROR1 transcript, Drs. John and Ford deduced that ROR1V3 encoded a cytoplasmic ROR1 protein lacking an apparent signal peptide necessary for transport to the cell surface, which they presumed made it unlikely to function as a surface receptor for Wingless/Integrated (Wnt) factors. Moreover, they speculated that studies evaluating ROR1 via immunohistochemistry using any one of several anti-ROR1 mAbs actually may have detected cytoplasmic protein encoded by ROR1V3 and that anti-cancer therapies targeting surface ROR1 thus would be ineffective against "cytoplasmic ROR1-positive" cancers that express predominately ROR1V3. We generated lentivirus vectors driving the expression of full-length ROR1 or the ROR1v3 upstream of an internal ribosome entry site (IRES) of the gene encoding a red fluorescent reporter protein. Although we find that cells that express ROR1 have surface and cytoplasmic ROR1 protein, cells that express ROR1v3 neither have surface nor cytoplasmic ROR1, which is consistent with our finding that ROR1v3 lacks an in-frame initiation codon for ribosomal translation into protein. We conclude that the detection of ROR1 protein in various cancers cannot be ascribed to the expression of ROR1v3.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Basic research of targeting ROR1 in malignant mesothelioma
    Nakagawa, Nozomu
    Ochi, Nobuaki
    Yamane, Hiromichi
    Fukazawa, Takuya
    Naomoto, Yoshio
    Takigawa, Nagio
    [J]. CANCER SCIENCE, 2018, 109 : 476 - 476
  • [32] IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis
    Weiwei Lin
    Rui Niu
    Seong-Min Park
    Yan Zou
    Sung Soo Kim
    Xue Xia
    Songge Xing
    Qingshan Yang
    Xinhong Sun
    Zheng Yuan
    Shuchang Zhou
    Dongya Zhang
    Hyung Joon Kwon
    Saewhan Park
    Chan Il Kim
    Harim Koo
    Yang Liu
    Haigang Wu
    Meng Zheng
    Heon Yoo
    Bingyang Shi
    Jong Bae Park
    Jinlong Yin
    [J]. Nature Communications, 14
  • [33] IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis
    Lin, Weiwei
    Niu, Rui
    Park, Seong-Min
    Zou, Yan
    Kim, Sung Soo
    Xia, Xue
    Xing, Songge
    Yang, Qingshan
    Sun, Xinhong
    Yuan, Zheng
    Zhou, Shuchang
    Zhang, Dongya
    Kwon, Hyung Joon
    Park, Saewhan
    Kim, Chan Il
    Koo, Harim
    Liu, Yang
    Wu, Haigang
    Zheng, Meng
    Yoo, Heon
    Shi, Bingyang
    Park, Jong Bae
    Yin, Jinlong
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
  • [34] Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling
    Balaian, Larissa
    Donohoe, Mary
    Mondala, Phoebe
    Widhopf, George F., II
    Ghia, Emanuela M.
    Ball, Edward D.
    Kulidjian, Anna
    Van der Werf, Inge
    Kipps, Thomas J.
    Jamieson, Catriona
    [J]. BLOOD, 2022, 140 : 3356 - 3357
  • [35] Genetic interactions between Ror2 and Wnt9a, Ror1 and Wnt9a and Ror2 and Ror1: Phenotypic analysis of the limb skeleton and palate in compound mutants
    Weissenboeck, Martina
    Latham, Richard
    Nishita, Michiru
    Wolff, Lena Ingeborg
    Ho, Hsin-Yi Henry
    Minami, Yasuhiro
    Hartmann, Christine
    [J]. GENES TO CELLS, 2019, 24 (04) : 307 - 317
  • [36] Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
    Daneshmanesh, Amir Hossein
    Porwit, Anna
    Hojjat-Farsangi, Mohammad
    Jeddi-Tehrani, Mahmood
    Tamm, Katja Pokrovskaja
    Grander, Dan
    Lehmann, Soren
    Norin, Stefan
    Shokri, Fazel
    Rabbani, Hodjattallah
    Mellstedt, Hakan
    Osterborg, Anders
    [J]. LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 843 - 850
  • [38] Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
    Henry, C. E.
    Llamosas, E.
    Djordjevic, A.
    Hacker, N. F.
    Ford, C. E.
    [J]. ONCOGENESIS, 2016, 5 : e226 - e226
  • [39] Development of a next generation ROR1 targeting Protein Drug Conjugate (PDC).
    Cotton, Graham
    Thom, Jennifer
    Trumper, Paul
    Bell, Stacey
    Wappett, Mark
    Barelle, Caroline
    Kovaleva, Marina
    Porter, Andrew
    McLean, Estelle
    Saladino, Chiara
    McCann, Aidan
    Cranston, Aaron
    Harrison, Tim
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [40] Shock and ROR! Targeting ROR1 and ROR2 in a preclinical patient-derived model of ovarian cancer
    Henry, Claire E.
    Hacker, Neville F.
    Ford, Caroline E.
    [J]. CANCER RESEARCH, 2018, 78 (13)